Market Overview

According to fortune business insights, the global hemato oncology testing market size was valued at USD 4.54 billion in 2025. The market is projected to grow from USD 4.84 billion in 2026 to USD 8.45 billion by 2034, exhibiting a CAGR of 7.2% during the forecast period. North America dominated the global hemato oncology testing market with a market share of 40.96% in 2025.

The analysis shows that growth is driven by the rising prevalence of blood disorders and the increasing adoption of advanced and easier-to-run tests for detection. For instance, the National Institutes of Health estimated 66,890 new cases of leukemia were expected in the U.S. in 2025. This trend, coupled with a growing emphasis on preventive care and screening, indicates a strong and rising demand for hemato oncology testing worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche AG (Switzerland)
• Abbott (U.S.)
• Danaher Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• BD (U.S.)
• Invivoscribe, Inc. (U.S.)
• Invitae Corporation (U.S.)

Segments

High Test Volume to Drive Assay Kits & Reagents Segment Growth

Based on products & services, the market is divided into assay kits & reagents, services, and instruments & platforms. The assay kits & reagents segment holds the largest market share due to high test volumes, repetitive purchases, and growing awareness, which are further boosted by new product introductions.

Higher Prevalence to Drive Lymphoma Segment Growth